Analyst Research

Report Title Price
Provider: GlobalData
Provider: Finlabo SIM Spa
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DiaSorin SpA Confirms FY 2013 Revenues and EBITDA Guidance

Friday, 10 May 2013 07:57am EDT 

DiaSorin SpA announced that it has confirmed the Company's revenues and EBITDA guidance for fiscal year 2013. The Company expects to report for fiscal year 2013 revenues with a growth rate between 2% and 4% at CER compared with fiscal year 2012 and EBITDA in line with the absolute value of fiscal year 2012 at CER, with an absorption from Molecular business equal to about EUR 6 million, as a result of investments required in the development of the new business. The Company reported for fiscal year 2012 revenues of EUR 433.76 million and EBITDA of EUR 169.56 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report for fiscal year 2013 revenues of EUR 446.96 million and EBITDA of EUR 171.44 million. 

Company Quote

0.1 +0.30%
19 Dec 2014